Common questions about Euflexxa injection (FAQ)
Q: How is Euflexxa different from other knee injections?
A: Official documents describe Euflexxa as a specific type of viscosupplementation agent made of sodium hyaluronate. Its active ingredient is non-avian, meaning it is not sourced from birds but is produced through bioengineered bacterial fermentation. This substance has a high molecular weight and is typically administered as a series of three injections.
Q: Can Euflexxa be used for joints other than the knee?
A: According to the official product information, Euflexxa is indicated only for the treatment of osteoarthritis of the knee. The safety and effectiveness of injecting the substance into joints other than the knee have not been established in formal safety assessments.
Q: Can Euflexxa be used by people with diabetes?
A: Official regulatory documents list contraindications only for individuals with known hypersensitivity (allergy) to hyaluronate products and those with existing infections or severe skin disease at the injection site. Diabetes is not listed as a contraindication in the official product information.
Q: Is it safe to get the injection if I am taking blood thinners?
A: Some official documents list active anticoagulation therapy (use of blood thinners) or hemophilia as a precaution or contraindication for this type of intra-articular injection. This is due to the potential procedural risk of bleeding from the injection. Regulatory precautions recommend that individuals discuss the use of any anti-coagulation therapy with their prescribing healthcare provider before the procedure.
Q: Do I need to change my activities after getting Euflexxa?
A: Official documents mandate that patients avoid strenuous physical activities, such as jogging, heavy lifting, or standing for prolonged periods (more than one hour), for 48 hours following each injection. The official documents do not specify mandatory activity changes beyond this 48-hour period.
Q: How long does the effect of Euflexxa typically last?
A: Clinical study outcomes indicate that patients may reach the maximum benefits of a single course of Euflexxa therapy for a duration of up to six months or longer. The purpose of the injection is to provide temporary mechanical support and relief for the symptoms of knee osteoarthritis.
Q: What should I do if the injection site feels warm or red?
A: Injection site reactions, including temporary redness, warmth, or pain, are common adverse events. Official patient guidance recommends informing a healthcare provider if symptoms such as redness, warmth, or pain are severe, worsen, or persist beyond 48 hours. Persistent reactions may be associated with more serious adverse reactions documented in the safety profile.
Q: Is Euflexxa used as a substitute for knee surgery?
A: The product information indicates that Euflexxa is used as a treatment for osteoarthritis of the knee in patients who have not responded adequately to conservative non-pharmacologic therapy and simple pain medications. It is one non-surgical treatment option described in regulatory documents.
Q: Can Euflexxa injections be used for younger patients with knee pain?
A: Official safety and effectiveness data have not been established for use in pediatric patients (under 18 years of age) or in younger adults (under 21 years of age). This means that there is a lack of established safety and effectiveness data for use in this population, according to official product information.
Q: How long does it usually take to feel the effects of Euflexxa?
A: Clinical study results indicate that patients may experience initial pain relief as early as one week after the first injection, with continued improvement often observed after subsequent injections in the series. As with any medical treatment, the response time can vary.
Q: Is Euflexxa covered by most insurance plans?
A: Authoritative patient support information indicates that most private insurance plans and Medicare provide coverage for Euflexxa. However, specific coverage details, including co-pays and requirements, can vary significantly depending on the individual plan.
Q: Is there any research that summarizes the effectiveness of Euflexxa?
A: A key clinical trial that measured outcomes over a 12-week period showed that a significant percentage of patients achieved a 'pain-free' outcome, as defined by the WOMAC pain subscale. This finding reflects the outcome observed in the studied patient population.
Q: What does the research say about repeating the Euflexxa series?
A: Official prescribing information indicates that the safety and effectiveness of repeat treatment cycles of Euflexxa have not been formally established. This means that while some patients may receive repeat courses, there are no definitive long-term regulatory studies addressing the safety of this practice.
Q: Can Euflexxa injections cause weight gain?
A: The official side effect profile lists common localized and general reactions such as joint pain, headache, and nausea. Clinical study data and regulatory documents do not indicate a direct link between Euflexxa injections and weight gain.
Q: Is Euflexxa considered a permanent solution for knee pain?
A: Euflexxa is classified as a viscosupplementation agent that provides temporary mechanical support and pain relief for a period of months. It is not described in official documents as a treatment that permanently corrects the condition.
Q: What is the general success rate reported in Euflexxa studies?
A: Clinical trial data indicated that nearly two-thirds of patients achieved a 'pain-free' status (as defined by the WOMAC pain scores) at the end of the 12-week study period. The study measured success as a significant improvement in pain symptoms from the start of the study.
Q: If the first injection doesn't help, should I still get the others in the series?
A: The official protocol is a complete course of three injections administered once weekly for three consecutive weeks. The effectiveness of a treatment cycle consisting of fewer than three injections has not been established in official safety and efficacy assessments.
Q: Does the FDA or other agencies have a safety warning about Euflexxa?
A: Regulatory documents contain a section of Important Safety Information that outlines contraindications, precautions, and risks of serious adverse reactions, such as anaphylaxis (a severe allergic reaction) or joint infection. This information is available for review with a healthcare provider.
Q: Is Euflexxa effective if I have severe, end-stage osteoarthritis?
A: Clinical trials included patients who presented with a wide range of knee pain severity, specifically those with moderate to severe pain related to their knee osteoarthritis. Effectiveness was measured against these populations, which included patients with high pain scores.
Q: Can people with shellfish allergies use Euflexxa?
A: Official documents state that Euflexxa's active ingredient is produced via non-avian, bacterial fermentation, meaning it does not contain substances derived from birds, such as eggs. Shellfish is not listed as a specific contraindication, but patient guidance recommends informing the healthcare provider of all known allergies, including food allergies.
Q: Can Euflexxa be given in both knees at the same time?
A: Euflexxa is administered per knee by a healthcare professional. If treatment is performed in both knees, the procedural guidelines require that a separate, single-use, pre-filled syringe must be used for each knee joint.
